Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2018 Jan 14

PMID 29330211

Citations 9

Authors

Zhonghan Zhang

Yaxiong Zhang

Gang Chen

Shaodong Hong

Yunpeng Yang

Wenfeng Fang

Fan Luo

Xi Chen

Yuxiang Ma

Yuanyuan Zhao

Jianhua Zhan

Cong Xue

Xue Hou

Ting Zhou

Shuxiang Ma

Fangfang Gao

Yan Huang

Likun Chen

Ningning Zhou

Hongyun Zhao

Li Zhang

Affiliations

Soon will be listed here.

Abstract

Background: The current antiemetic prophylaxis for patients treated with highly emetogenic chemotherapy (HEC) included the olanzapine-based triplet and neurokinin-1 receptor antagonists (NK-1RAs)-based triplet. However, which one shows better antiemetic effect remained unclear.

Materials And Methods: We systematically reviewed 43 trials, involving 16,609 patients with HEC, which compared the following antiemetics at therapeutic dose range for the treatment of chemotherapy-induced nausea and vomiting: olanzapine, aprepitant, casopitant, fosaprepitant, netupitant, and rolapitant. The main outcomes were the proportion of patients who achieved no nausea, complete response (CR), and drug-related adverse events. A Bayesian network meta-analysis was performed.

Results: Olanzapine-based triple regimens showed significantly better no-nausea rate in overall phase and delayed phase than aprepitant-based triplet (odds ratios 3.18, 3.00, respectively), casopitant-based triplet (3.78, 4.12, respectively), fosaprepitant-based triplet (3.08, 4.10, respectively), rolapitant-based triplet (3.45, 3.20, respectively), and conventional duplex regimens (4.66, 4.38, respectively). CRs of olanzapine-based triplet were roughly equal to different NK-1RAs-based triplet but better than the conventional duplet. Moreover, no significant drug-related adverse events were observed in olanzapine-based triple regimens when compared with NK-1RAs-based triple regimens and duplex regimens. Additionally, the costs of olanzapine-based regimens were obviously much lower than the NK-1RA-based regimens.

Conclusion: Olanzapine-based triplet stood out in terms of nausea control and drug price but represented no significant difference of CRs in comparison with NK-1RAs-based triplet. Olanzapine-based triple regimens should be an optional antiemetic choice for patients with HEC, especially those suffering from delayed phase nausea.

Implications For Practice: According to the results of this study, olanzapine-based triple antiemetic regimens were superior in both overall and delayed-phase nausea control when compared with various neurokinin-1 receptor antagonists-based triple regimens in patients with highly emetogenic chemotherapy (HEC). Olanzapine-based triplet was outstanding in terms of nausea control and drug price. For cancer patients with HEC, especially those suffering from delayed-phase nausea, olanzapine-based triple regimens should be an optional antiemetic choice.

Citing Articles

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.

Notini G, Naldini M, Sica L, Viale G, Rognone A, Zambelli S Front Oncol. 2024; 14:1374547.

PMID: 38529378 PMC: 10961432. DOI: 10.3389/fonc.2024.1374547.

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents.

Herrstedt J, Celio L, Hesketh P, Zhang L, Navari R, Chan A Support Care Cancer. 2023; 32(1):47.

PMID: 38127246 PMC: 10739516. DOI: 10.1007/s00520-023-08221-4.

Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).

Sakai H, Tsurutani J, Ozaki Y, Ishiguro H, Nozawa K, Watanabe K BMJ Open. 2023; 13(4):e070304.

PMID: 37012013 PMC: 10083740. DOI: 10.1136/bmjopen-2022-070304.

Effect of Shengbai Decoction on Chemotherapy-Induced Myelosuppression and Survival of Gastric Cancer Patients After Radical Resection: A Retrospective Study.

Yao L, Feng W, Tao Y, Tang C Med Sci Monit. 2022; 28:e935936.

PMID: 35185148 PMC: 8876002. DOI: 10.12659/MSM.935936.

Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial.

Sakai C, Shimokawa M, Iihara H, Fujita Y, Ikemura S, Hirose C Oncologist. 2021; 26(6):e1066-e1072.

PMID: 33811782 PMC: 8176968. DOI: 10.1002/onco.13772.

References

Kitayama H, Tsuji Y, Sugiyama J, Doi A, Kondo T, Hirayama M . Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study. Int J Clin Oncol. 2015; 20(6):1051-6. DOI: 10.1007/s10147-015-0823-6. View

Rapoport B, Jordan K, Boice J, Taylor A, Brown C, Hardwick J . Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2009; 18(4):423-31. DOI: 10.1007/s00520-009-0680-9. View

Weinstein C, Jordan K, Green S, Camacho E, Khanani S, Beckford-Brathwaite E . Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol. 2015; 27(1):172-8. PMC: 4684151. DOI: 10.1093/annonc/mdv482. View

Rapoport B, Schwartzberg L, Chasen M, Powers D, Arora S, Navari R . Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016; 57:23-30. DOI: 10.1016/j.ejca.2015.12.023. View

Herrington J, Jaskiewicz A, Song J . Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008; 112(9):2080-7. DOI: 10.1002/cncr.23364. View

Bymaster F, Falcone J, Bauzon D, Kennedy J, Schenck K, DeLapp N . Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol. 2001; 430(2-3):341-9. DOI: 10.1016/s0014-2999(01)01399-1. View

Passik S, Navari R, Jung S, Nagy C, Vinson J, Kirsh K . A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest. 2004; 22(3):383-8. DOI: 10.1081/cnv-200029066. View

Chawla S, Grunberg S, Gralla R, Hesketh P, Rittenberg C, Elmer M . Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003; 97(9):2290-300. DOI: 10.1002/cncr.11320. View

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice J . Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol. 2011; 29(11):1495-501. DOI: 10.1200/JCO.2010.31.7859. View

10.

Navari R, Nagy C, Le-Rademacher J, Loprinzi C . Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol. 2016; 14(4):141-7. DOI: 10.12788/jcso.0245. View

11.

de Wit R, Herrstedt J, Rapoport B, Carides A, Carides G, Elmer M . Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol. 2003; 21(22):4105-11. DOI: 10.1200/JCO.2003.10.128. View

12.

Berger M, Ettinger D, Aston J, Barbour S, Bergsbaken J, Bierman P . NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017; 15(7):883-893. DOI: 10.6004/jnccn.2017.0117. View

13.

Moher D, Jadad A, Nichol G, Penman M, Tugwell P, Walsh S . Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials. 1995; 16(1):62-73. DOI: 10.1016/0197-2456(94)00031-w. View

14.

Wang X, Feng Y, Chen Y, Gao B, Han B . A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Sci Rep. 2014; 4:4813. PMC: 5381218. DOI: 10.1038/srep04813. View

15.

Hesketh P, Grunberg S, Gralla R, Warr D, Roila F, de Wit R . The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052.... J Clin Oncol. 2003; 21(22):4112-9. DOI: 10.1200/JCO.2003.01.095. View

16.

Zhang Y, Yang Y, Zhang Z, Fang W, Kang S, Luo Y . Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis. J Natl Cancer Inst. 2016; 109(2). DOI: 10.1093/jnci/djw217. View

17.

Navari R, Gray S, Kerr A . Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011; 9(5):188-95. DOI: 10.1016/j.suponc.2011.05.002. View

18.

Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y . Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer. 2015; 51(10):1274-82. DOI: 10.1016/j.ejca.2015.03.024. View

19.

Ito Y, Karayama M, Inui N, Kuroishi S, Nakano H, Nakamura Y . Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer. 2014; 84(3):259-64. DOI: 10.1016/j.lungcan.2014.03.017. View

20.

Kim J, Jang J, Kim J, Sung Y, Cho C, Lee M . Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. Support Care Cancer. 2016; 25(3):801-809. DOI: 10.1007/s00520-016-3463-0. View